MX2020006494A - Anticuerpos de cadena pesada que se unen a cd22. - Google Patents
Anticuerpos de cadena pesada que se unen a cd22.Info
- Publication number
- MX2020006494A MX2020006494A MX2020006494A MX2020006494A MX2020006494A MX 2020006494 A MX2020006494 A MX 2020006494A MX 2020006494 A MX2020006494 A MX 2020006494A MX 2020006494 A MX2020006494 A MX 2020006494A MX 2020006494 A MX2020006494 A MX 2020006494A
- Authority
- MX
- Mexico
- Prior art keywords
- heavy chain
- chain antibodies
- antibodies binding
- antibodies
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609759P | 2017-12-22 | 2017-12-22 | |
| PCT/US2018/067299 WO2019126756A1 (en) | 2017-12-22 | 2018-12-21 | Heavy chain antibodies binding to cd22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006494A true MX2020006494A (es) | 2020-11-24 |
Family
ID=65041936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006494A MX2020006494A (es) | 2017-12-22 | 2018-12-21 | Anticuerpos de cadena pesada que se unen a cd22. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11873336B2 (https=) |
| EP (1) | EP3728319A1 (https=) |
| JP (2) | JP7486421B2 (https=) |
| KR (2) | KR102823263B1 (https=) |
| CN (1) | CN111683966B (https=) |
| AU (1) | AU2018392088A1 (https=) |
| BR (1) | BR112020012554A2 (https=) |
| CA (1) | CA3086665A1 (https=) |
| CL (3) | CL2020001703A1 (https=) |
| CO (1) | CO2020008925A2 (https=) |
| CR (1) | CR20200322A (https=) |
| EA (1) | EA202091557A1 (https=) |
| EC (1) | ECSP20042489A (https=) |
| IL (1) | IL275498B1 (https=) |
| JO (1) | JOP20200157B1 (https=) |
| MX (1) | MX2020006494A (https=) |
| MY (1) | MY204744A (https=) |
| NI (1) | NI202000050A (https=) |
| PE (1) | PE20201171A1 (https=) |
| PH (1) | PH12020550964A1 (https=) |
| SA (1) | SA520412283B1 (https=) |
| SG (1) | SG11202005880XA (https=) |
| UA (1) | UA128757C2 (https=) |
| WO (1) | WO2019126756A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| JP2023518049A (ja) | 2020-03-16 | 2023-04-27 | ユニバーシティ オブ サザン カリフォルニア | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 |
| KR20210143097A (ko) * | 2020-05-19 | 2021-11-26 | (주)이노베이션바이오 | Cd22에 특이적인 항체 및 이의 용도 |
| AU2021307644A1 (en) * | 2020-07-16 | 2023-02-16 | Legend Biotech Ireland Limited | CD22 binding molecules and uses thereof |
| JP7846667B2 (ja) | 2020-07-16 | 2026-04-15 | レジェンド バイオテック アイルランド リミテッド | Ｃｄ２０結合分子及びその使用 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| US8207306B2 (en) | 2008-09-19 | 2012-06-26 | Medimmune, Llc | Targeted binding agents directed to sonic hedgehog homolog and uses thereof |
| JP6126782B2 (ja) | 2008-10-01 | 2017-05-10 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体 |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| JP2014515598A (ja) | 2011-03-10 | 2014-07-03 | エイチシーオー アンティボディ， インク． | 二重特異性三鎖抗体様分子 |
| WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| SG10201608307WA (en) | 2012-04-20 | 2016-11-29 | Emergent Product Dev Seattle | Cd3 binding polypeptides |
| EP2841459A4 (en) | 2012-04-26 | 2016-04-13 | Bioatla Llc | ANTI-CD22 ANTIBODIES |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| HRP20231356T1 (hr) | 2012-12-14 | 2024-02-16 | Omniab, Inc. | Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| DK3105252T3 (da) | 2014-02-12 | 2019-10-14 | Michael Uhlin | Bispecifikke antistoffer til anvendelse ved stamcelletransplantation |
| US9139649B2 (en) * | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| SI3221357T1 (sl) | 2014-11-20 | 2020-09-30 | F. Hoffmann-La Roche Ag | Pogoste lahke verige in načini uporabe |
| CN104710528B (zh) * | 2015-03-13 | 2019-02-15 | 西北农林科技大学 | 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用 |
| CN116063544A (zh) | 2016-02-03 | 2023-05-05 | 安进研发（慕尼黑）股份有限公司 | Bcma和cd3双特异性t细胞接合抗体构建体 |
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| US20200138865A1 (en) | 2017-06-30 | 2020-05-07 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Anti-b-cell maturation antigen chimeric antigen receptors with human domains |
| KR20200044094A (ko) | 2017-09-13 | 2020-04-28 | 테네오바이오, 인코포레이티드 | 엑토효소에 결합하는 중쇄 항체 |
| WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| RU2020124623A (ru) | 2017-12-27 | 2022-01-27 | Тенеобио, Инк. | Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон |
| PL3823990T3 (pl) | 2018-07-20 | 2026-04-20 | TeneoTwo, Inc. | Przeciwciała łańcucha ciężkiego wiążące się z cd19 |
| CN112839959A (zh) | 2018-09-21 | 2021-05-25 | 特尼奥生物股份有限公司 | 用于纯化异源二聚多特异性抗体的方法 |
| BR112021000173A2 (pt) | 2018-10-26 | 2021-05-04 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd38 |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| WO2021127489A1 (en) | 2019-12-18 | 2021-06-24 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| CA3185805A1 (en) | 2020-04-29 | 2021-11-04 | Teneoone, Inc. | Methods of treating multiple myeloma |
| TWI838621B (zh) | 2020-04-29 | 2024-04-11 | 美商泰尼歐萬公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| IL299027A (en) | 2020-06-30 | 2023-02-01 | Teneobio Inc | Multispecific antibodies that bind BCMA |
| TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| CA3211138A1 (en) | 2021-02-25 | 2022-09-01 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
| WO2022183101A1 (en) | 2021-02-26 | 2022-09-01 | Teneobio, Inc. | Anti-muc1-c antibodies and car-t structures |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| PE20232050A1 (es) | 2021-04-06 | 2023-12-27 | Teneobio Inc | Anticuerpos anti-cd19 y estructuras car-t |
| WO2022221698A1 (en) | 2021-04-16 | 2022-10-20 | Teneobio, Inc. | Anti-cd20 antibodies and car-t structures |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
-
2018
- 2018-12-21 WO PCT/US2018/067299 patent/WO2019126756A1/en not_active Ceased
- 2018-12-21 CN CN201880083056.4A patent/CN111683966B/zh active Active
- 2018-12-21 UA UAA202004621A patent/UA128757C2/uk unknown
- 2018-12-21 EA EA202091557A patent/EA202091557A1/ru unknown
- 2018-12-21 CR CR20200322A patent/CR20200322A/es unknown
- 2018-12-21 KR KR1020207021048A patent/KR102823263B1/ko active Active
- 2018-12-21 MX MX2020006494A patent/MX2020006494A/es unknown
- 2018-12-21 AU AU2018392088A patent/AU2018392088A1/en not_active Abandoned
- 2018-12-21 MY MYPI2020003176A patent/MY204744A/en unknown
- 2018-12-21 SG SG11202005880XA patent/SG11202005880XA/en unknown
- 2018-12-21 CA CA3086665A patent/CA3086665A1/en active Pending
- 2018-12-21 EP EP18836782.5A patent/EP3728319A1/en active Pending
- 2018-12-21 BR BR112020012554-7A patent/BR112020012554A2/pt active Search and Examination
- 2018-12-21 US US16/956,502 patent/US11873336B2/en active Active
- 2018-12-21 JP JP2020534858A patent/JP7486421B2/ja active Active
- 2018-12-21 PE PE2020000809A patent/PE20201171A1/es unknown
- 2018-12-21 KR KR1020257020109A patent/KR20250093583A/ko active Pending
-
2020
- 2020-06-18 IL IL275498A patent/IL275498B1/en unknown
- 2020-06-20 CL CL2020001703A patent/CL2020001703A1/es unknown
- 2020-06-20 SA SA520412283A patent/SA520412283B1/ar unknown
- 2020-06-21 JO JOJO/P/2020/0157A patent/JOP20200157B1/ar active
- 2020-06-22 NI NI202000050A patent/NI202000050A/es unknown
- 2020-06-22 PH PH12020550964A patent/PH12020550964A1/en unknown
- 2020-07-21 CO CONC2020/0008925A patent/CO2020008925A2/es unknown
- 2020-07-22 EC ECSENADI202042489A patent/ECSP20042489A/es unknown
-
2022
- 2022-08-18 CL CL2022002247A patent/CL2022002247A1/es unknown
-
2023
- 2023-12-07 US US18/532,880 patent/US20240117046A1/en active Pending
-
2024
- 2024-02-05 JP JP2024015399A patent/JP2024062992A/ja active Pending
- 2024-08-01 CL CL2024002319A patent/CL2024002319A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020006494A (es) | Anticuerpos de cadena pesada que se unen a cd22. | |
| MX2021012205A (es) | Anticuerpos de cadena pesada que se unen al psma. | |
| AR119746A1 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| DOP2022000229A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| ECSP22083174A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
| BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
| CL2018003582A1 (es) | Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567) | |
| MX2020010881A (es) | Construcciones de anticuerpos anti-ror. | |
| CL2019002605A1 (es) | Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas. | |
| MX2023009874A (es) | Anticuerpos anti-psma y estructuras car-t. | |
| CL2023003073A1 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
| BR112017018940A2 (pt) | anticorpos sítio-específicos projetados e métodos de uso | |
| MX2023009882A (es) | Anticuerpos anti-muc1-c y estructuras car-t. | |
| CO2023013500A2 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| CO2022015105A2 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CL2023002284A1 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas |